56 related articles for article (PubMed ID: 9721869)
41. Inhibitors of Serine/Threonine Protein Phosphatases: Biochemical and Structural Studies Provide Insight for Further Development.
Swingle MR; Honkanen RE
Curr Med Chem; 2019; 26(15):2634-2660. PubMed ID: 29737249
[TBL] [Abstract][Full Text] [Related]
42. Keeping the centrosome cycle on track. Genome stability.
Winey M
Curr Biol; 1996 Aug; 6(8):962-4. PubMed ID: 8805324
[TBL] [Abstract][Full Text] [Related]
43. A New Mode of Mitotic Surveillance.
Lambrus BG; Holland AJ
Trends Cell Biol; 2017 May; 27(5):314-321. PubMed ID: 28188027
[TBL] [Abstract][Full Text] [Related]
44. Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.
Zhang Q; Fan Z; Zhang L; You Q; Wang L
J Med Chem; 2021 Jul; 64(13):8916-8938. PubMed ID: 34156850
[TBL] [Abstract][Full Text] [Related]
45. Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering.
Ducrey E; Castrogiovanni C; Meraldi P; Nowak-Sliwinska P
Apoptosis; 2021 Jun; 26(5-6):248-252. PubMed ID: 33870441
[TBL] [Abstract][Full Text] [Related]
46. The effects of cantharidin and cantharidin derivates on tumour cells.
Liu D; Chen Z
Anticancer Agents Med Chem; 2009 May; 9(4):392-6. PubMed ID: 19442040
[TBL] [Abstract][Full Text] [Related]
47. Cantharidin-based small molecules as potential therapeutic agents.
Puerto Galvis CE; Vargas Méndez LY; Kouznetsov VV
Chem Biol Drug Des; 2013 Nov; 82(5):477-99. PubMed ID: 23809227
[TBL] [Abstract][Full Text] [Related]
48. The molecular basis of drug-induced G2 arrest in mammalian cells.
Rao PN
Mol Cell Biochem; 1980 Jan; 29(1):47-57. PubMed ID: 6154231
[TBL] [Abstract][Full Text] [Related]
49. Biotherapeutic potential and synthesis of okadaic acid.
Forsyth CJ; Dounay AB; Sabes SF; Urbanek RA
Ernst Schering Res Found Workshop; 2000; (32):57-102. PubMed ID: 11077606
[No Abstract] [Full Text] [Related]
50. Small molecule inhibitors of serine/threonine protein phosphatases.
McCluskey A; Sakoff JA
Mini Rev Med Chem; 2001 May; 1(1):43-55. PubMed ID: 12369990
[TBL] [Abstract][Full Text] [Related]
51. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents.
Sakoff JA; McCluskey A
Curr Pharm Des; 2004; 10(10):1139-59. PubMed ID: 15078146
[TBL] [Abstract][Full Text] [Related]
52. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
53. The role of p53 in the response to mitotic spindle damage.
Meek DW
Pathol Biol (Paris); 2000 Apr; 48(3):246-54. PubMed ID: 10858957
[TBL] [Abstract][Full Text] [Related]
54. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
55. Fostriecin: chemistry and biology.
Lewy DS; Gauss CM; Soenen DR; Boger DL
Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
[TBL] [Abstract][Full Text] [Related]
56. The role of protein phosphatase type-2A in the Xenopus cell cycle: initiation of the G2/M transition.
Lee TH
Semin Cancer Biol; 1995 Aug; 6(4):203-9. PubMed ID: 8541515
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
